L Hernandez

Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States

L Hernandez, Shien Guo, Elizabeth Kinter et al. · Journal of Medical Economics · 2016 · 28 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis

L Hernandez, Tereza Lanitis, Clifford Cele et al. · Journal of Managed Care & Specialty Pharmacy · 2018 · 26 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +14

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)

Óscar Fernández, Eduardo Durán, Teresa Ayuso et al. · PLoS ONE · 2017 · 25 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +14

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

L Hernandez, Shien Guo, Hector Toro‐Díaz et al. · Journal of Medical Economics · 2016 · 21 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice

José Meca-Lallana, L Hernandez, Ana B. Caminero et al. · European Neurology · 2016 · 11 citations

Life Sciences, Neurology, Pharmacotherapy +14